The New England Journal of Medicine Publishes Results from Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121), an Investigational BCMA-Directed CAR T Cell TherapyBusiness Wire • 02/24/21
BLUE Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds bluebird bio, Inc. Investors of Class Action and Encourages Shareholders to Contact the FirmBusiness Wire • 02/24/21
BLUE ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against bluebird bio, Inc.– BLUEGlobeNewsWire • 02/24/21
Breaking Alert: Rosen, A Trusted and Leading Law Firm, Encourages bluebird bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - BLUENewsfile Corp • 02/23/21
bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational ProgressBusiness Wire • 02/23/21
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 02/23/21
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. (BLUE) InvestorsBusiness Wire • 02/22/21
Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against bluebird bio, Inc. – BLUEGlobeNewsWire • 02/22/21
BLUEBIRD BIO, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against bluebird bio, Inc.PRNewsWire • 02/19/21
BLUE Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021PRNewsWire • 02/19/21
ROSEN, A TOP RANKED LAW FIRM, Encourages bluebird bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – BLUEGlobeNewsWire • 02/18/21
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmNewsfile Corp • 02/18/21
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmPRNewsWire • 02/18/21
BLUE Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies bluebird bio, Inc. Investors of Class Action and Encourages Shareholders to Contact the FirmGlobeNewsWire • 02/18/21
BLUE INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc.PRNewsWire • 02/18/21
BREAKING ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages bluebird bio, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline - BLUEPRNewsWire • 02/18/21
Shareholder Alert: Robbins LLP Announces That Bluebird Bio, Inc. (BLUE) is Being Sued for Misleading ShareholdersBusiness Wire • 02/17/21
bluebird (BLUE) Down on Suspension of Sickle Cell Disease StudiesZacks Investment Research • 02/17/21
Bluebird Bio Temporarily Suspends Sickle Cell Gene Therapy Studies Following Incidences of Blood CancerBenzinga • 02/16/21
Bluebird Stock Collapses To 7-Year Low On Safety Concern In Gene TherapyInvestors Business Daily • 02/16/21
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmBusiness Wire • 02/16/21
